Transient hypophysitis in a patient treated by duvelisib for chronic lymphocytic leukemia
Letter to the Editor
First Online:
Received:
Accepted:
- 153 Downloads
Keywords
Imatinib Chronic Lymphocytic Leukemia Imatinib Mesylate Hypopituitarism Immune Checkpoint
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
Notes
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
References
- 1.Fain JS, Naeim F, Becker DP, Van Herle A, Yan-Go F, Petrus L, Vinters HV (1992) Chronic lymphocytic leukemia presenting as a pituitary mass lesion. Can J Neurol Sci 19:239–242PubMedGoogle Scholar
- 2.Owen C, Assouline S, Kuruvilla J, Uchida C, Bellingham C, Sehn L (2015) Novel therapies for chronic lymphocytic leukemia: a Canadian perspective. Clin Lymphoma Myeloma Leuk 15:627–634CrossRefPubMedGoogle Scholar
- 3.Lodish MB, Stratakis CA (2010) Endocrine side effects of broad-acting kinase inhibitors. Endocr Relat Cancer 17:233–244CrossRefGoogle Scholar
- 4.Joshi MN, Whitelaw BC, Palomar MT, Wu Y, Carroll PV (2016) Immune checkpoint inhibitor-related hypophysitis and endocrine dysfunction: clinical review. Clin Endocrinol 85:331–339CrossRefGoogle Scholar
- 5.Bilgir O, Kebapcilar L, Bilgir F, Sarì I, Oner P, Karaca B, Alacacioglu I (2010) Is there any relationship between imatinib mesylate medication and hypothalamic-pituitary-adrenal axis dysfunction? Int J Clin Pract 64:45–50CrossRefPubMedGoogle Scholar
Copyright information
© Springer-Verlag Berlin Heidelberg 2017